DrugPatentWatch Database Preview

Olmesartan medoxomil - Generic Drug Details

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for olmesartan medoxomil and what is the scope of olmesartan medoxomil freedom to operate?

Olmesartan medoxomil is the generic ingredient in two branded drugs marketed by Daiichi Sankyo, Accord Hlthcare, Alembic Pharms Ltd, Alkem Labs Ltd, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Pharms Usa Inc, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-six drug master file entries for olmesartan medoxomil. Twenty-five suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for olmesartan medoxomil

US Patents:	0
Tradenames:	2
Applicants:	13
NDAs:	13
Drug Master File Entries:	36
Suppliers / Packagers:	25
Bulk Api Vendors:	93
Clinical Trials:	127
Patent Applications:	4,670
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for olmesartan medoxomil
DailyMed Link:	olmesartan medoxomil at DailyMed

Pharmacology for olmesartan medoxomil

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for olmesartan medoxomil

Angiotensin II Type 1 Receptor Blockers

Antihypertensive Agents

Synonyms for olmesartan medoxomil

(5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-h

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-i midazole-5-carboxylate

(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-iMidazole-5-carboxylate

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl]-1H-imidazole-5-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)imidazole-4-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate

(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate

(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazol-5-carboxylate;

(5-Methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate

(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate

144689-63-4

1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester

1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

5-(1-Hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

5-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-3-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-3H-IMIDAZOLE-4-CARBOXYLIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER

5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

689O634

6M97XTV3HD

A808260

AB0012006

AB01275443_02

AB01275443_03

AB01275443-01

AB1009487

AC-1601

AC1L2Y71

AK-72894

AKOS015894907

AKOS015914772

AN-1125

AOB3863

BC208264

BC209016

BCP9000555

BDBM50442892

Benevas

Benicar

Benicar (TN)

BENICAR HCT

Benicar, Olmetec,Olmesartan

Berlin-Chemie Brand of Olmesartan Medoxomil

Bio-0071

BR-72894

BRD-K78485176-001-02-9

BSPBio_003491

C29H30N6O6

CAS-144689-63-4

CCG-221184

CCG-39596

CHEBI:31932

CHEBI:93384

CHEMBL1200692

CPD004727564

Cs 866

CS-0577

CS-866

CS-866DM

CS-866RN

CS866

D01204

D07UBG

DE-092

DR003267

DSSTox_CID_25924

DSSTox_GSID_45924

DSSTox_RID_81226

DTXSID9045924

EBD35964

Forest Brand of Olmesartan Medoxomil

FT-0601603

GTPL591

HE311789

HMS1922L15

HMS2089K18

HMS2093K16

HMS3651E13

HY-17005

I06-0025

I14-41691

J-501595

J10058

KBio2_002490

KBio2_005058

KBio2_007626

KBio3_002711

KBioGR_001040

KBioSS_002498

KS-00000IVQ

KS-1182

L001061

LS-181818

MCULE-2480015750

MFCD00944911

MLS006010109

NCGC00095136-01

NCGC00095136-02

NCGC00095136-03

NSC-758924

NSC758924

NU006784

O0510

Olmesartan (medoxomil)

Olmesartan medoximil

Olmesartan medoxomil (Benicar)

Olmesartan medoxomil (JAN/USAN)

Olmesartan medoxomil (JP17/USAN)

Olmesartan medoxomil [USAN:INN:BAN]

Olmesartan medoxomil for system suitability, European Pharmacopoeia (EP) Reference Standard

Olmesartan medoxomil tablets (JP17)

Olmesartan medoxomil, >=98% (HPLC)

Olmesartan medoxomil, European Pharmacopoeia (EP) Reference Standard

Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material

Olmesartan medoxomil, United States Pharmacopeia (USP) Reference Standard

Olmesartan medoxomil|4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-carboxylic acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Olmesartanmedoxomil

Olmetec

Olmetec (TN)

Olmetec; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1Htetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Olsertain

Olvance

Openvas

Pharmakon1600-01505205

RP17784

S-1787

s1604

SAM001246634

Sankyo Brand of Olmesartan Medoxomil

SBI-0206741.P001

SC-17112

SCHEMBL16403

SMR002203616

SPBio_000431

Spectrum_001944

SPECTRUM1505205

Spectrum2_000506

Spectrum3_001676

Spectrum4_000740

Spectrum5_001556

SR-05000001987

SR-05000001987-2

ST24031498

STL451024

Tox21_111445

UNII-6M97XTV3HD

UQGKUQLKSCSZGY-UHFFFAOYSA-N

votume

Z1550675457

ZINC4149248

Tentative approvals for OLMESARTAN MEDOXOMIL

Applicant	Application No.	Strength	Dosage Form
		5MG	TABLET; ORAL
		40MG	TABLET; ORAL
		20MG	TABLET; ORAL

US Patents and Regulatory Information for olmesartan medoxomil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662-002	Apr 24, 2017	AB	RX	No	No
Alembic Pharms Ltd	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	203012-003	Apr 24, 2017	AB	RX	No	No
Torrent Pharms Ltd	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	202375-002	Apr 24, 2017	AB	RX	No	No
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662-001	Apr 24, 2017	AB	RX	No	No

  Purchase this report

or, see our see our flat-rate plans

Expired US Patents for olmesartan medoxomil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286-001	Apr 25, 2002
Daiichi Sankyo	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286-004	Apr 25, 2002
Daiichi Sankyo	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286-003	Apr 25, 2002

  Purchase this report

or, see our see our flat-rate plans